Last reviewed · How we verify
SA55 Injection
At a glance
| Generic name | SA55 Injection |
|---|---|
| Sponsor | Sinovac Life Sciences Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of the Anti-COVID-19 Antibody SA55 for Injection in Patients With Hematological Disorders Who Are Persistently Positive for COVID-19 (NA)
- SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients (PHASE2)
- SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SA55 Injection CI brief — competitive landscape report
- SA55 Injection updates RSS · CI watch RSS
- Sinovac Life Sciences Co., Ltd. portfolio CI